Conclusion: This study provides proof-of-concept data demonstrating an oxytocin analog with extended in vivo stability and improved potency to reduce food intake and body weight in DIO animals which could mark a new avenue in anti-obesity drug interventions. The gene discussed is OXT; the disease is obesity due to melanocortin 4 receptor deficiency.